XOMA is transitioning into a diversified royalty holding company, yet its financial performance remains heavily tethered to the unpredictable timing of milestone payments across its 70-asset portfolio. While the company maintains a robust liquidity position wi...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 12, 2026 | $0.17-10.5% vs $0.19 | $14M+0.3% vs $14M |
Q2 2026 Mar 18, 2026 | $0.26+300.0% vs -$0.13 | $14M+24.5% vs $11M |
Q4 2025 Nov 12, 2025 | $0.70+1850.0% vs -$0.04 | $9M-18.5% vs $11M |
Q3 2025 Aug 13, 2025 | $0.48+500.0% vs -$0.12 | $13M+39.9% vs $9M |
Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.
Benchmark XOMA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for XOMA Royalty Corp. (XOMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.17 | $503.77M | 27.51 | 83.06% | 60.81% | 34.12% | 0.76% | |
| $57.65 | $25.55B | 32.03 | 5.06% | 32.15% | 8.35% | — | |
| $3.60 | $249.82M | -1.14 | 105.77% | -311.11% | -33.22% | — | |
| $101.30 | $4.89B | 16.06 | 5.91% | 33.21% | 49.73% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $123.96 | $9.13B | -21.19 | — | — | -42.78% | — |
XOMA Royalty Corp. (XOMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
XOMA Royalty Corp. (XOMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 14, 2026·SEC
Jun 12, 2026·SEC
May 22, 2026·SEC
Get notified when XOMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XOMA Royalty Corp. (XOMA) stock FAQ — growth, dividends, profitability & financials explained
XOMA Royalty Corp. (XOMA) reported $36.2M in revenue for fiscal year 2025. This represents a 906% increase from $3.6M in 1996.
XOMA Royalty Corp. (XOMA) grew revenue by 83.1% over the past year. This is strong growth.
Yes, XOMA Royalty Corp. (XOMA) is profitable, generating $31.5M in net income for fiscal year 2025 (60.8% net margin).
Yes, XOMA Royalty Corp. (XOMA) pays a dividend with a yield of 0.76%. This makes it attractive for income-focused investors.
XOMA Royalty Corp. (XOMA) has a return on equity (ROE) of 34.1%. This is excellent, indicating efficient use of shareholder capital.
XOMA Royalty Corp. (XOMA) generated $6.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
